THC produces intoxication; CBD does not. Both come from the same plant, both legal in Maryland. Ratios, regulatory differences, what to buy at ReLeaf.
THC is the cannabis compound that produces intoxication; CBD does not. Both come from the same cannabis plant, both interact with the body's endocannabinoid system, and both are sold legally in Maryland — but they behave differently in product form, in dose, and in legal classification. ReLeaf Shop in Baltimore carries THC products under the state's adult-use program plus CBD-forward and CBD-dominant ratios from brands like Doctor Solomon's, Wyld, and Camino. This post is informational and not medical advice; consult a clinician for case-specific questions about cannabis and your health.
Cannabis sativa produces a family of compounds called cannabinoids. THC (tetrahydrocannabinol) and CBD (cannabidiol) are the two most abundant. Both are produced by the same plant; the ratio depends on the cultivar, the growing conditions, and how the plant is processed. Published research on the cannabis cannabinoid system covers the biology in detail.
The legal-and-retail distinction in 2026 is not which plant a compound came from, but where the compound came from on the plant and at what concentration. Hemp-derived CBD (from low-THC cannabis plants) and cannabis-derived CBD (from higher-THC plants) are chemically identical molecules. They're regulated differently because of where they sit in federal and state law.
THC produces intoxication. It binds to CB1 receptors in the central nervous system — the same receptors involved in mood, memory, pain perception, and appetite. The intoxication is dose-dependent: a 2mg edible is meaningfully different from a 20mg edible, and individual response varies with body weight, food intake, tolerance, and a half-dozen other factors.
Maryland regulates THC under the adult-use cannabis program (for 21+ recreational buyers) and the medical cannabis program (for state-certified patients). Both programs require licensed retailers, lab testing, and labeling. Recreational sales carry a 9% sales tax; medical sales are tax-exempt. Both programs use the same Maryland Cannabis Administration framework — cannabis.maryland.gov has the regulatory details.
What that means at ReLeaf: every THC product on the shelf is lab-tested, batch-numbered, dose-labeled, and sold to adults 21+. There is no legal gray-area THC at a Maryland dispensary. The gas-station "delta-8" and "THC-A flower" products sold outside the regulated dispensary system operate under different (and often murkier) federal rules; they are not what ReLeaf sells.
CBD does not produce intoxication. It has a different binding profile than THC — it doesn't activate CB1 receptors directly. Research on CBD's pharmacology covers a range of mechanisms including serotonin-receptor interaction, anti-inflammatory pathways, and effects on the endocannabinoid system that don't involve CB1 binding. Project CBD's science overview is a reliable starting point for the published research; the FDA's CBD policy page covers the federal regulatory posture.
CBD products at ReLeaf come from cannabis-derived CBD inside the Maryland dispensary system — meaning the CBD product is licensed, tested, and labeled the same way as a THC product even though it contains little or no THC. This is different from the hemp-derived CBD products sold at health food stores, supplement shops, and Amazon, which are federally legal (under the 2018 Farm Bill threshold of less than 0.3% THC) but are not part of the Maryland cannabis program.
The practical difference for a Baltimore shopper: cannabis-dispensary CBD is regulated under the state's strict testing program; hemp-derived CBD bought elsewhere is regulated under a patchwork of federal and state hemp rules with much wider variability in actual content. For shoppers who want CBD specifically because of the regulated testing, the dispensary path is the more verifiable one.
Most cannabis-derived CBD products at ReLeaf are not pure CBD. They're blended with some amount of THC, expressed as a ratio. The numbers can be confusing the first time; here's how to read them:
1:1 THC:CBD. Equal parts. A typical 1:1 gummy might be 5mg THC and 5mg CBD per piece. Customers report the CBD softens or "rounds" the THC effect compared to a THC-only product.
1:2 or 1:3 THC:CBD. CBD-leaning. More CBD than THC. Still produces some THC effect at higher doses but the CBD weighting changes the experience.
20:1 CBD:THC. CBD-dominant. The trace THC is below the threshold most users report any intoxication from. The product is functionally a CBD-forward product.
THC-only. Most flower, most concentrates, most edibles. No CBD listed on the label.
When you ask a budtender for a "CBD product," they'll usually ask back which direction in the ratio grid you want. The 1:1 and 20:1 ratios are the two most-common Maryland retail SKUs in this category.
Patterns we hear at the counter, paraphrased and not as medical guidance:
Customers asking for CBD often describe wanting "the wind-down without the high," interest in topicals for soreness, or specifically saying their schedule doesn't allow intoxication that day. The 20:1 ratio and CBD-forward topicals (Doctor Solomon's roll-ons, balms) come up most often in these conversations.
Customers asking for THC describe the standard cannabis use cases — relaxation in the evening, social context, creative or focus contexts depending on the strain. The product mix is wide.
Customers asking for "something in between" are usually pointed toward 1:1 ratios or to CBD-forward edibles with a small THC component. The conversation tends to start with how much intoxication the customer wants, not with how much CBD they want.
The format breakdown for shopping CBD-leaning or THC-leaning at a Baltimore dispensary:
Flower. Almost entirely THC-dominant in Maryland's retail market. CBD-dominant flower exists but is rare in the legal dispensary case. If you want a low-THC smokable, the path is to look for high-CBD-percentage strains on the label.
Edibles. Where most ratio products live. Camino's Sparkling Pear (5mg THC + small CBD), 1:1 Wana gummies, Wyld's CBD-forward lines when they ship in. The Baltimore edibles guide goes into the SKU-level details.
Vapes. Mostly THC-dominant. CBD vape cartridges exist but make up a small share of the Maryland market. CBD-dominant disposables turn up occasionally.
Topicals. The CBD-dominant category that's most reliably stocked. Doctor Solomon's at ReLeaf is the most-recognized CBD-forward topical line and a budtender go-to for shoppers asking about non-intoxicating cannabis. Our cannabis topicals at ReLeaf post covers the category.
THC produces intoxication; CBD does not. Both come from the cannabis plant, but THC binds to the CB1 receptors that drive the "high" while CBD interacts with the endocannabinoid system differently and through several other receptor systems. Both can be present in the same product at different ratios.
No. CBD on its own is non-intoxicating. Products labeled as CBD-only or CBD-dominant (like 20:1 ratios) don't produce a noticeable high at standard doses. Products that blend CBD with THC will produce a high proportional to the THC content.
Yes. ReLeaf Shop carries cannabis-derived CBD products including 20:1 CBD-dominant tinctures, gummies, and topicals (especially Doctor Solomon's). These are different from hemp-derived CBD products sold at health food stores — the dispensary versions are tested and labeled under Maryland's cannabis program.
The CBD molecule is identical. The regulatory framework, the testing, and the production controls are different. Hemp-derived CBD is federally legal under the 2018 Farm Bill at less than 0.3% THC; cannabis-derived CBD is sold under state cannabis programs with stricter lab testing and labeling. For shoppers who want regulated-and-tested CBD specifically, the dispensary path is the more verifiable one.
Equal parts THC and CBD by weight. A 1:1 gummy with 5mg per piece would have 5mg THC and 5mg CBD. Customers report the CBD component softens the THC effect compared to a THC-only product at the same THC dose.
Authority sources: Maryland Cannabis Administration, FDA CBD regulatory policy, Project CBD science library. ReLeaf coverage of related topics: cannabis topicals, the science behind THC, cannabis terpenes guide, and every cannabis brand at ReLeaf Shop.
This post is informational and does not constitute medical advice. Consult a clinician for case-specific questions about cannabis, CBD, THC, and your health.
